Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dyadic International Inc. (DYAI : NSDQ)

• Company Description    Dyadic International, Inc. is a leading genomics company with the groundbreaking technology that brings nature to the marketplace. Dyadic is poised to become a global leader in proteomics through the discovery, development, and manufacturing of novel products derived from the DNA of complex living organisms including humans found in the earth's biodiversity. Using its integrated technology platform, Dyadic develops biological products such as proteins, enzymes, polypeptides and small molecules for applications in large segments of the agricultural, industrial, chemical and biopharmaceutical industries. By utilizing a proprietary host organism, Dyadic's `one-stop shop` technology rapidly discovers and expresses eukaryotic genes the genes of complex living organisms and then manufactures those unique biological products for commercial application. Dyadic's systems overcome the inadequacy of existing gene discovery and product development techniques. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $1.07 Daily Weekly Monthly 20 Day Moving Average: 119,885 shares Shares Outstanding: 36.19 (millions) Market Capitalization: $38.72 (millions) Beta: 1.00 52 Week High: $2.20 52 Week Low: $0.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% 0.01% 12 Week -2.73% -6.75% Year To Date -38.86% -46.04%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1044 North U.S. Highway One Suite 201 - JUPITER,FL 33477 USA ph: 561-743-8333 fax: 561-743-8343 ir@dyadic.com http://www.dyadic.com

• General Corporate Information    Officers Mark A. Emalfarb - President and Chief Executive Officer Patrick Lucy - Chairman Ping W. Rawson - Chief Financial Officer Jack L. Kaye - Director Seth J. Herbst - Director Peer Information Dyadic International Inc. (CORR.) Dyadic International Inc. (RSPI) Dyadic International Inc. (CGXP) Dyadic International Inc. (BGEN) Dyadic International Inc. (GTBP) Dyadic International Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 26745T101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 36.19 Most Recent Split Date: (:1) Beta: 1.00 Market Capitalization: $38.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.17 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 9.36 EPS Growth vs. Year Ago Period: 14.29% vs. Previous Quarter: 14.29% Sales Growth vs. Year Ago Period: 150.52% vs. Previous Quarter: 145.43% ROE 09/30/25 - - 06/30/25 - -355.39 03/31/25 - -233.69 ROA 09/30/25 - - 06/30/25 - -60.66 03/31/25 - -59.37 Current Ratio 09/30/25 - - 06/30/25 - 2.02 03/31/25 - 3.98 Quick Ratio 09/30/25 - - 06/30/25 - 2.02 03/31/25 - 3.98 Operating Margin 09/30/25 - - 06/30/25 - -134.82 03/31/25 - -163.91 Net Margin 09/30/25 - - 06/30/25 - -134.84 03/31/25 - -163.94 Pre-Tax Margin 09/30/25 - - 06/30/25 - -134.70 03/31/25 - -163.77 Book Value 09/30/25 - - 06/30/25 - -0.02 03/31/25 - 0.03 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - 5.40 Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - 84.37

Powered by Zacks Investment Research ©